In conclusion, our findings imply that the T-type calcium channels are novel molecular targets to develop therapeutics to treat TAF1 ID syndrome and that SAK3 is an attractive drug candidate to treat TAF1 associated neurological disorders. This evidence concerns the gene TAF1 and nervous system disorder.